Document Type : Original Article

Authors

1 Department of Physiotherapy and Rehabilitation, School of Health Sciences, Izmir Katip Celebi University, Izmir, Turkey

2 Graduate School, Izmir University of Economics, Izmir, Turkey

3 Department of Neurology, Medical Point Hospital, Izmir University of Economics, Izmir, Turkey

4 Department of Neurology, Medical Point Hospital, Izmir University of Economics, Izmir, Turkey Multiple Sclerosis Research Association, Izmir University of Economics, Izmir, Turkey

Abstract

Background: Cognitive impairment is common in multiple sclerosis (MS) and can markedly influence individuals’ quality of life (QOL). Understanding the factors influencing cognitive dysfunction in MS is essential for developing targeted interventions. Smoking, a modifiable risk factor linked to numerous adverse outcomes in MS, has an unclear relationship with cognitive function. This comparative study with cross-sectional data collection aimed to examine the association between smoking and cognitive performance in persons with MS.
Methods: A total of 152 participants with MS were recruited, comprising 76 smokers and 76 non-smokers. Cognitive function was assessed using the Brief International Cognitive Assessment for MS (BICAMS), which includes the Symbol Digit Modalities Test (SDMT), California Verbal Learning Test-II (CVLT-II), and Brief Visuospatial Memory Test-Revised (BVMT-R). Cognitive impairment was defined as scores below 1.5 standard deviations (SDs) from the mean, and tobacco exposure was quantified in terms of pack-years. Analyses controlled for potential confounders such as age, education, and Expanded Disability Status Scale (EDSS) scores.
Results: Smokers performed significantly worse on the CVLT-II and BVMT-R (P < 0.05), while no differences were observed on the SDMT. After adjusting for confounders, only BVMT-R performance remained significantly associated with smoking status (P = 0.009, η²p  = 0.049). Smokers had higher odds of cognitive impairment on the BVMT-R [odds ratio (OR) = 11.8, P = 0.002]. Additionally, pack-year exposure correlated with declines in BVMT-R and CVLT-II scores (P < 0.05).
Conclusion: These findings indicate an association between smoking and cognitive performance in MS, particularly in visuospatial and verbal memory domains. Further research is needed to explore underlying mechanisms and inform clinical strategies.
 

Keywords

Main Subjects

  1. Di Pauli F, Reindl M, Ehling R, Schautzer F, Gneiss C, Lutterotti A, et al. Smoking is a risk factor for early conversion to clinically definite multiple sclerosis. Mult Scler 2008; 14(8): 1026-30.
  2. Healy BC, Ali EN, Guttmann CR, Chitnis T, Glanz BI, Buckle G, et al. Smoking and disease progression in multiple sclerosis. Arch Neurol 2009; 66(7): 858-64.
  3. Heydarpour P, Manouchehrinia A, Beiki O, Mousavi SE, Abdolalizadeh A, Lakeh MM, et al. Smoking and worsening disability in multiple sclerosis: A meta-analysis. Acta Neurol Scand 2018; 138(1): 62-9.
  4. Kahraman T, Ozdogar AT, Abasiyanik Z, Ozakbas S. Associations between smoking and walking, fatigue, depression, and health-related quality of life in persons with multiple sclerosis. Acta Neurol Belg 2021; 121(5): 1199-206.
  5. McKay KA, Tremlett H, Fisk JD, Patten SB, Fiest K, Berrigan L, et al. Adverse health behaviours are associated with depression and anxiety in multiple sclerosis: A prospective multisite study. Mult Scler 2016; 22(5): 685-93.
  6. Weiland TJ, Hadgkiss EJ, Jelinek GA, Pereira NG, Marck CH, van der Meer DM. The association of alcohol consumption and smoking with quality of life, disability and disease activity in an international sample of people with multiple sclerosis. J Neurol Sci 2014; 336(1-2): 211-9.
  7. Briggs FB, Gunzler DD, Ontaneda D, Marrie RA. Smokers with MS have greater decrements in quality of life and disability than non-smokers. Mult Scler 2017; 23(13): 1772-81.
  8. Amato MP, Prestipino E, Bellinvia A, Niccolai C, Razzolini L, Pastò L, et al. Cognitive impairment in multiple sclerosis: An exploratory analysis of environmental and lifestyle risk factors. PLoS One 2019; 14(10): e0222929.
  9. Kalmar JH, Gaudino EA, Moore NB, Halper J, Deluca J. The relationship between cognitive deficits and everyday functional activities in multiple sclerosis. Neuropsychology 2008; 22(4): 442-9.
  10. Abbatemarco JR, Ontaneda D, Nakamura K, Husak S, Wang Z, Alshehri E, et al. Comorbidity effect on processing speed test and MRI measures in multiple sclerosis patients. Mult Scler Relat Disord 2020; 46: 102593.
  11. Brochet B, Ruet A. Cognitive Impairment in Multiple Sclerosis With Regards to Disease Duration and Clinical Phenotypes. Front Neurol 2019; 10: 261.
  12. Sumowski JF, Benedict R, Enzinger C, Filippi M, Geurts JJ, Hamalainen P, et al. Cognition in multiple sclerosis: State of the field and priorities for the future. Neurology 2018; 90(6): 278-88.
  13. Roy S, Benedict RH, Drake AS, Weinstock-Guttman B. Impact of Pharmacotherapy on Cognitive Dysfunction in Patients with Multiple Sclerosis. CNS Drugs 2016; 30(3): 209-25.
  14. Goverover Y, Chiaravalloti ND, O'Brien AR, DeLuca J. Evidenced-Based Cognitive Rehabilitation for Persons With Multiple Sclerosis: An Updated Review of the Literature From 2007 to 2016. Arch Phys Med Rehabil 2018; 99(2): 390-407.
  15. Ozcan ME, Ince B, Bingöl A, Ertürk S, Altınöz MA, Karadeli HH, et al. Association between smoking and cognitive impairment in multiple sclerosis. Neuropsychiatr Dis Treat 2014; 10: 1715-9.
  16. Chow HH, Talbot J, Marstrand L, Lundell H, Roman Siebner H, Bach Søndergaard H, et al. Smoking, cardiovascular risk factors and LRP2 gene variation: Associations with disease severity, cognitive function and brain structure in primary progressive multiple sclerosis. Mult Scler Relat Disord 2021; 56: 103296.
  17. Alirezaei M, Forouzannia SM, Yarahmadi P, Sahraian MA, Owji M, Bidadian M, et al. Demographic features, behavioral measures, and clinical factors as predictors of cognitive function in patients with multiple sclerosis. Mult Scler Relat Disord 2021; 49: 102758.
  18. Bernaards CM, Twisk JW, Snel J, Van Mechelen W, Kemper HC. Is calculating pack-years retrospectively a valid method to estimate life-time tobacco smoking? A comparison between prospectively calculated pack-years and retrospectively calculated pack-years. Addiction 2001; 96(11): 1653-61.
  19. Langdon DW, Amato MP, Boringa J, Brochet B, Foley F, Fredrikson S, et al. Recommendations for a Brief International Cognitive Assessment for Multiple Sclerosis (BICAMS). Mult Scler 2012; 18(6): 891-8.
  20. Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 1983; 33(11): 1444-52.
  21. Ozakbas S, Yigit P, Cinar BP, Limoncu H, Kahraman T, Kösehasanoğulları G. The Turkish validation of the Brief International Cognitive Assessment for Multiple Sclerosis (BICAMS) battery. BMC Neurol 2017; 17(1): 208.